Skip to content

About
Science
Newsroom
Careers
Contact

Menu

About
Science
Newsroom
Careers
Contact

Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment

Post navigation

← Previous Scientific Publication

Next Scientific Publication →

Search for:

Recent Posts

Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Idiopathic Pulmonary Fibrosis Trial using TTI-101, a Novel STAT3 Inhibitor
Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 Inhibitor
Tvardi Therapeutics Announces Presentation of Data from the Phase 1 Trial of TTI-101, a STAT3 Inhibitor, in Advanced Solid Tumors at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Tvardi Therapeutics to Participate at the Cowen 43rd Annual Health Care Conference
Tvardi Therapeutics Announces First Patients Dosed in Phase 2 Trial of TTI-101 in Metastatic Breast Cancer

Recent Comments

Archives

August 2023
June 2023
May 2023
February 2023
January 2023
November 2022
October 2022
September 2022
May 2022
April 2022
December 2021
September 2021
June 2021
March 2021
January 2021
November 2020
July 2020
June 2020
May 2020
April 2019
March 2019
January 2019
December 2018
October 2018
September 2018

Categories

Media
Press Release

Meta

Log in
Entries feed
Comments feed
WordPress.org

Home
About
Our Science
Newsroom
Contact
FCOI
Privacy Policy
Terms of Use

Home
About
Our Science
Newsroom
Contact
FCOI
Privacy Policy
Terms of Use

Linkedin Twitter

Tvardi Therapeutics ©2023

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and Terms of Use.